Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porustobart + PD-1 inhibitors in advanced NEN and CRC
NCT05167071Phase 1Active, not recruiting
- Sponsor
- Harbour BioMed
- Start
- Dec 2021
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of porustobart in neuroendocrine neoplasms (NENs), colorectal cancer (CRC) and solid tumor (3 arms), sponsored by Harbour BioMed. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
porustobart
03
Conditions
neuroendocrine neoplasms (NENs)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05167071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05167071.